XNAS · Healthcare · Biotechnology
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | Q1 2026 | -0.06 | -0.08 | -33.33% | $0 | ❌ Miss | -1.70% | +15.21% | — |
| 2026-03-31 | Q4 2025 | -0.10 | -0.08 | +20.00% | $0 | ✅ Beat | +5.45% | -21.51% | -18.64% |
| 2025-11-14 |
| Q3 2025 |
| -0.11 |
| -0.13 |
| -18.18% |
| $0 |
| ❌ Miss |
| — |
| — |
| — |
| 2025-08-14 | Q2 2025 | -0.16 | -0.12 | +25.00% | $0 | ✅ Beat | +0.00% | +3.19% | +42.82% |
| 2025-03-31 | Q4 2024 | -0.21 | -0.19 | +9.52% | $0 | ✅ Beat | +3.28% | +8.61% | +12.30% |
| 2024-11-13 | Q3 2024 | -0.20 | -0.18 | +10.00% | $0 | ✅ Beat | -5.17% | -2.93% | -27.24% |
| 2024-08-13 | Q2 2024 | -0.16 | -0.20 | -25.00% | $0 | ❌ Miss | -7.56% | +2.22% | +20.44% |
| 2024-05-15 | Q1 2024 | -0.16 | -0.19 | -18.75% | $0 | ❌ Miss | +2.61% | +1.63% | -14.38% |
Showing last 8 quarters.